We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Abbott (ABT) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
The upcoming report from Abbott (ABT - Free Report) is expected to reveal quarterly earnings of $1.25 per share, indicating an increase of 9.7% compared to the year-ago period. Analysts forecast revenues of $11.07 billion, representing an increase of 6.7% year over year.
The current level reflects a downward revision of 0.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain Abbott metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Net sales- Nutrition' will reach $2.24 billion. The estimate indicates a change of +4.3% from the prior-year quarter.
The consensus estimate for 'Net sales- Medical Devices- Diabetes Care' stands at $1.94 billion. The estimate indicates a year-over-year change of +17.5%.
Analysts' assessment points toward 'Net sales- Diagnostics' reaching $2.22 billion. The estimate indicates a change of +1% from the prior-year quarter.
According to the collective judgment of analysts, 'Net sales- Established Pharmaceuticals' should come in at $1.37 billion. The estimate indicates a change of +6.1% from the prior-year quarter.
The consensus among analysts is that 'Net sales- Diagnostics- U.S.' will reach $832.19 million. The estimate indicates a year-over-year change of +2.5%.
Analysts expect 'Net sales- Diagnostics- International' to come in at $1.38 billion. The estimate indicates a year-over-year change of +0.1%.
The combined assessment of analysts suggests that 'Net sales- Nutrition- International' will likely reach $1.26 billion. The estimate indicates a year-over-year change of +3.5%.
It is projected by analysts that the 'Net sales- Nutrition- U.S.' will reach $985.20 million. The estimate suggests a change of +5.6% year over year.
The collective assessment of analysts points to an estimated 'Net sales- Medical Devices- Neuromodulation- International' of $53.47 million. The estimate indicates a year-over-year change of +4.8%.
The average prediction of analysts places 'Net sales- Medical Devices- Rhythm Management- U.S.' at $312.05 million. The estimate points to a change of +6.9% from the year-ago quarter.
Analysts forecast 'Net sales- Medical Devices- Rhythm Management- International' to reach $334.64 million. The estimate suggests a change of +6.2% year over year.
Based on the collective assessment of analysts, 'Net sales- Medical Devices- Structural Heart- U.S.' should arrive at $304.28 million. The estimate suggests a change of +17.9% year over year.
Abbott shares have witnessed a change of -2.7% in the past month, in contrast to the Zacks S&P 500 composite's +4% move. With a Zacks Rank #2 (Buy), ABT is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Countdown to Abbott (ABT) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
The upcoming report from Abbott (ABT - Free Report) is expected to reveal quarterly earnings of $1.25 per share, indicating an increase of 9.7% compared to the year-ago period. Analysts forecast revenues of $11.07 billion, representing an increase of 6.7% year over year.
The current level reflects a downward revision of 0.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain Abbott metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Net sales- Nutrition' will reach $2.24 billion. The estimate indicates a change of +4.3% from the prior-year quarter.
The consensus estimate for 'Net sales- Medical Devices- Diabetes Care' stands at $1.94 billion. The estimate indicates a year-over-year change of +17.5%.
Analysts' assessment points toward 'Net sales- Diagnostics' reaching $2.22 billion. The estimate indicates a change of +1% from the prior-year quarter.
According to the collective judgment of analysts, 'Net sales- Established Pharmaceuticals' should come in at $1.37 billion. The estimate indicates a change of +6.1% from the prior-year quarter.
The consensus among analysts is that 'Net sales- Diagnostics- U.S.' will reach $832.19 million. The estimate indicates a year-over-year change of +2.5%.
Analysts expect 'Net sales- Diagnostics- International' to come in at $1.38 billion. The estimate indicates a year-over-year change of +0.1%.
The combined assessment of analysts suggests that 'Net sales- Nutrition- International' will likely reach $1.26 billion. The estimate indicates a year-over-year change of +3.5%.
It is projected by analysts that the 'Net sales- Nutrition- U.S.' will reach $985.20 million. The estimate suggests a change of +5.6% year over year.
The collective assessment of analysts points to an estimated 'Net sales- Medical Devices- Neuromodulation- International' of $53.47 million. The estimate indicates a year-over-year change of +4.8%.
The average prediction of analysts places 'Net sales- Medical Devices- Rhythm Management- U.S.' at $312.05 million. The estimate points to a change of +6.9% from the year-ago quarter.
Analysts forecast 'Net sales- Medical Devices- Rhythm Management- International' to reach $334.64 million. The estimate suggests a change of +6.2% year over year.
Based on the collective assessment of analysts, 'Net sales- Medical Devices- Structural Heart- U.S.' should arrive at $304.28 million. The estimate suggests a change of +17.9% year over year.
View all Key Company Metrics for Abbott here>>>Abbott shares have witnessed a change of -2.7% in the past month, in contrast to the Zacks S&P 500 composite's +4% move. With a Zacks Rank #2 (Buy), ABT is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .